Shionogi Spurns Europe, Places Bets On Asia For Global Expansion - Bio Expo Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Shionogi, set on global expansion, has rejected initial plans to expand into Europe, instead turning to emerging markets in Asia
You may also be interested in...
Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning
TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)
Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning
TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)
Japan Earnings Roundup: Shinogi & Co.'s China Deal And Astellas Pharma Inc.'s Label Woes
Shionogi rebounds from U.S. acquisition woes with C&O Pharmaceutical for China; Astellas ponders Mirabegron's reproductive warning.